474 reports of this reaction
2.3% of all LANREOTIDE ACETATE reports
#8 most reported adverse reaction
HEADACHE is the #8 most commonly reported adverse reaction for LANREOTIDE ACETATE, manufactured by Ipsen Biopharmaceuticals, Inc.. There are 474 FDA adverse event reports linking LANREOTIDE ACETATE to HEADACHE. This represents approximately 2.3% of all 20,256 adverse event reports for this drug.
Patients taking LANREOTIDE ACETATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for LANREOTIDE ACETATE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for LANREOTIDE ACETATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 474 FDA reports for LANREOTIDE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.3% of all adverse event reports for LANREOTIDE ACETATE, making it a notable side effect.
If you experience headache while taking LANREOTIDE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.